Barclays Maintains an 'Equalweight' on Eli Lilly (LLY); Takeaways From Meeting with Mgmt

Barclays maintains an 'Equalweight' on Eli Lilly (NYSE: LLY) price target of $39.00.

Analyst, C. Anthony Butler, said, "We hosted a dinner with LLY management at our 2012 Global Healthcare Conference (David Ricks, Senior Vice President of LLY Bio-Medicines, and Phil Johnson, Vice President of Investor Relations)...Sentiment towards solanezumab unchanged as management continues to set low expectations...Management optimistic about their IL-17 in psoriasis, anti-BAFF antibody for RA, NERI for depression, novel basal insulins and the peak sales opportunity of ramucirumab in breast cancer...Also discussed were potential areas of additional cost savings as well as the Japan pricing environment."

For an analyst ratings summary and ratings history on Eli Lilly click here. For more ratings news on Eli Lilly click here.

Shares of Eli Lilly closed at $40.20 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Lilly files six lawsuits over illegal sales of unapproved retatrutide
• JD.com (JD) Reiterated at Buy by Benchmark Amid Earnings Recovery
• SoundThinking (SSTI) PT Lowered to $8 at Cantor Fitzgerald